GPT and fibrosis: More recently, a randomized four‐arm Indian trial compared saroglitazar, vitamin E, their combination, and lifestyle control, finding that saroglitazar reduced ALT while the combination achieved the broadest benefits, including significant reductions in liver stiffness measure (primary surrogate of fibrosis) and CAP, with concurrent improvement in glycemic and lipid parameters, suggesting potential additive or synergistic effects of dual therapy on liver and metabolic endpoints.